SGCB and kidney disorder: Since severe renal diseases are mostly due to downregulation of NO‐sGC‐cGMP signal transduction, the current phase II and III clinical trials for vericiguat, praliciguat, and olinciguat are undertaken for the treatment of kidney diseases.61, 62, 63